Systemic medical ozone has proved to help in several viral diseases, chronic obstructive pulmonary disease and chronic inflammation process. The investigators are sure that its application to COVID-19 patients, as an adjuvant therapy, will improve the health status of these individuals.
Due to the extreme world situation caused by COVID19 pandemic, the investigators consider
unethical not to try any treatment option with a justified rationale.
The investigators have explained that medical ozone therapy has a clear scientific basement
thanks to all preclinical and clinical investigation already published. It can be classified
as chemical stressor that produces a modulation in the redox balance and immunity. Moreover,
it is easy and safe to administer with insignificant side effects.
The efficacy in viral diseases has been proved in publications together the modulation of
interleukin 6 and other proinflammatory cytokines that could potentially help in COVID19
patients. The improve of exchange of gases and microcirculation will surely contribute to
enhance this patients' health status.
As explained above, the investigators propose to carry out a randomized control trial to
evaluate the safety and efficacy of systemic ozone (indirect endovenous) in these patients.
Other: Systemic indirect endovenous ozone therapy
200 mL at 40 mcg/mL of medical ozone / oxygen in 200 mL of patients blood mixed in an homologated device for the procedure.
Inclusion Criteria:
- COVID19 virus detected in oro/nasopharynx
- mild ill according WHO numeric scale
- mild ill according Berlin criteria
- non intubated patients
- signed informed consent
Exclusion Criteria:
- patients treated with systemic ozone in the last 6 months
- patients treated before with systemic ozone and referring any side effect
- glucose-6-phosphate-dehydrogenase deficit
- other severe concomitant disease apart from COVID19
- psychiatric disease specified in axis I of l Diagnostic and Statistical Manual of
Mental Disorders, 5 edition, but major depression
- patients not capable of understanding the study methods and targets
- pregnant woman
SEOT
Valencia, Spain
Investigator: Jose Baeza Noci, MD, PhD
Contact: +34963177800
jose.baeza@uv.es
Jose Baeza Noci, MD, PhD
+34963177800
jose.baeza@uv.es
Francisco J Hidalgo Tallón, MD, PhD
fjht63@gmail.com